Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Trounced the Market on Tuesday

By Eric Volkman - May 18, 2021 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reacted positively to a company presentation at an industry convention.

What happened

Amarin (AMRN 4.89%) rose to end Tuesday nearly 5.1% higher after the company provided details from clinical studies of the components of its one commercialized drug.

So what

In a presentation at the American College of Cardiology's Annual Scientific Session, Amarin presented findings from a study of a key ingredient of that drug, cardiovascular treatment Vascepa (marketed as Vazkepa in the EU). 

A doctor and a patient in consultation.

Image source: Getty Images.

In the presentation, the biotech company's Chief Scientific Officer Steven Ketchum highlighted the company's pronouncement that in the REDUCE-IT study gauging the efficacy of its product, it "significantly reduced first and total primary and key secondary endpoint events by approximately 30% to 40% in patients with dyslipidemia."

Dyslipidemia is a condition in which patients have blood lipids such as cholesterol that are too high or too low. Cardiovascular disease is the leading cause of death across the globe.

Speaking of the key ingredient in Vascepa, Ketchum said that "we are hopeful that our continued support of robust scientific presentation of the clinical effects and unique multifactorial mechanisms of action of icosapent ethyl will lead to a greater understanding and usage of this important product to help appropriate at-risk patients."

Now what

At the end of March, Amarin won crucial approval for Vazkepa throughout the EU. Unlike the U.S., where the company lost a high-stakes patent infringement lawsuit, it will be the sole drug of its kind in that jurisdiction. The company's presentation, it seems, effectively highlighted the vast potential of this product.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.69 (4.89%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.